Pontifax et al. in €14.5m round for Step Pharma

Pontifax recently joined the series-A round in a second closing of €8.6m. Investors Kurma Partners, BPI France Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute took part in a first closing for the round amounting to €5.9m in June 2016, according to a source close to the deal.

BPI France used its Biothérapies Innovantes Et Maladies Rares fund for the investment.

The additional funding will be used to advance the company's oral immunomodulators targeting cytidine triphosphate synthase 1 (CTPS1) into clinical testing.

Company
Founded in 2014 and headquartered in Paris, Step Pharma is a biotechnology company discovering and developing proprietary small-molecule therapeutics for the treatment of autoimmune diseases.

It focuses on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of autoimmune diseases.

People
Step Pharma – Geoffroy de Ribains (CEO, co-founder).
Kurma Partners – Vanessa Malier (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• BPI France
• IDInvest Partners (AGF Private Equity)